Disease Synopsis
Overview
Drugs and Clinical Candidates
Clinical Trials (visual)
Clinical Trials (text)
Cell Line Models
Chemistry

Lymphoma - Overview - Disease Synopsis

Drugs & Clinical Candidates


48 drugs have received FDA approval for Lymphoma . Acalabrutinib, Axicabtagene Ciloleucel, Belinostat, Bendamustine Hydrochloride, Bexarotene, Bleomycin Sulfate, Bortezomib, Brigatinib, CH5424802, COPANLISIB HYDROCHLORIDE, Carmustine, Ceritinib, Chlorambucil, Crizotinib, Cyclophosphamide, Cytarabine, Dacarbazine, Denileukin Diftitox, Dexamethasone Sodium Phosphate, Doxorubicin Hydrochloride, Duvelisib, Ibrutinib, Idelalisib, Lenalidomide, Lomustine, Lorlatinib, Mechlorethamine Hydrochloride, Methotrexate Sodium, Nelarabine, Nivolumab, Obinutuzumab, Palifermin, Pembrolizumab, Plerixafor Octahydrochloride, Pralatrexate, Prednisolone Sodium Phosphate, Procarbazine Hydrochloride, Rasburicase, Recombinant Interferon Alfa-2b, Rituximab, Romidepsin, Tisagenlecleucel, Vedotin, Venetoclax, Vinblastine Sulfate, Vincristine Sulfate, Vorinostat and YTTRIUM Y 90 IBRITUMOMAB TIUXETAN
534 drugs have a clinical trial registered for Lymphoma.

Sources: cancer.gov and clinicaltrials.gov
(see details)

Clinical Trials


There are 4647 clinical trials for Lymphoma,
3208 of which have one or more drug interventions,
1439 with no drug intervention.

Sources: cancer.gov and clinicaltrials.gov
(see details)

Cell Line Models


There are 359 Cell Line Models for Lymphoma.

Source: COSMIC
(see details)

Chemistry


There are 3428 Compounds which have been tested in Lymphoma , 2320 <= 500nM potency.

Source: ChEMBL
(see details)

Mappings


Please note the mappings below are based on an imperfect algorithm. If you notice any anomalies please report them to us.

The following terms have been mapped from clinicaltrials.gov mesh condition terms to Lymphoma:
Burkitt Lymphoma
Composite Lymphoma
Enteropathy-Associated T-Cell Lymphoma
Hodgkin Disease
Intraocular Lymphoma
Leukemia-Lymphoma, Adult T-Cell
Lymphatic Metastasis
Lymphoma
Lymphoma, AIDS-Related
Lymphoma, B-Cell
Lymphoma, B-Cell, Marginal Zone
Lymphoma, Extranodal NK-T-Cell
Lymphoma, Follicular
Lymphoma, Large B-Cell, Diffuse
Lymphoma, Large-Cell, Anaplastic
Lymphoma, Large-Cell, Immunoblastic
Lymphoma, Mantle-Cell
Lymphoma, Non-Hodgkin
Lymphoma, Primary Cutaneous Anaplastic Large Cell
Lymphoma, Primary Effusion
Lymphoma, T-Cell
Lymphoma, T-Cell, Cutaneous
Lymphoma, T-Cell, Peripheral
Lymphomatoid Granulomatosis
Lymphomatoid Papulosis
Plasmablastic Lymphoma
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Pseudolymphoma

The following terms have been mapped from cancer.gov to Lymphoma:
Anaplastic large cell lymphoma. It is used in:Patients whose disease is systemic (affects the whole body) and has not gotten better after treatment with combination chemotherapy
B-cell non-Hodgkin lymphoma. It is used in patients who have been treated with chemotherapy or with rituximab and have not gotten better or have had a relapse. Ibritumomab tiuxetan is combined with a radioactive substance and given with rituximab, as a type of radioimmunotherapy
B-cell non-Hodgkin lymphoma (NHL) that is CD20 positive.It is used alone in patients with follicular lymphoma or low-grade lymphoma that has relapsed or is refractory (doesn??????t respond to treatment)
B-cell non-Hodgkin lymphoma (NHL) that is indolent (slow-growing) and got worse during or within 6 months after treatment with rituximab
B-cell non-Hodgkin lymphoma (NHL), including the following types:Diffuse large B-cell lymphoma (DLBCL)
Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is used in patients who have already received at least one type of treatment
Chronic lymphocytic leukemia and small lymphocytic lymphoma
Chronic lymphocytic leukemia or small lymphocytic lymphoma that has relapsed (come back) or is refractory (does not respond to treatment). It is used in adults who have received at least two other therapies
Classical Hodgkin lymphoma in adults whose disease has relapsed (come back) or gotten worse after either:An autologous stem cell transplant and treatment with brentuximab vedotin; or
Cutaneous T-cell lymphoma (a certain type). It is used in patients whose disease has not gotten better with other treatment or has recurred (come back)
Cutaneous T-cell lymphoma in patients who have already been treated with at least one other type of systemic therapy
Cutaneous T-cell lymphoma that has not gotten better with other chemotherapy or that has recurred (come back)
Cutaneous anaplastic large cell lymphoma that is primary. It is used in patients who have received other systemic therapy
DLBCL in patients who had follicular lymphoma
DLBCL in patients who had follicular lymphoma.
Diffuse large B-cell lymphoma. It is used with anthracycline chemotherapy in adults whose disease has not been treated
Follicular lymphoma that is aggressive. It is used with combination chemotherapy in adults
Follicular lymphoma that has relapsed or is refractory. It is used in adults who have received at least two other systemic therapies
Follicular lymphoma that has relapsed. It is used in adults who have received at least two other systemic treatments
Follicular lymphoma. It is used in adults with follicular lymphoma that:Has relapsed or is refractory (does not respond to treatment)
Follicular lymphoma. It is used:With bendamustine hydrochloride and then by itself to treat follicular lymphoma that relapsed after treatment with rituximab or did not respond to the treatment
High-grade B-cell lymphoma
Hodgkin lymphoma
Hodgkin lymphoma in adults and children. It is used in patients whose disease is refractory (does not respond to treatment) or has relapsed after at least three other types of treatment.????
Hodgkin lymphoma in patients whose disease has not gotten better with other chemotherapy
Hodgkin lymphoma that is advanced
Hodgkin lymphoma. It is used in patients whose disease has not gotten better with other types of treatment or has recurred (come back)
Hodgkin lymphoma. It is used with other drugs in patients whose disease has not gotten better with other treatment or has recurred (come back)
Hodgkin lymphoma.It is used after an autologous stem cell transplant (ASCT) in patients who have a high risk that the cancer will recur (come back) or get worse
It is used with chemotherapy in patients with stage III or stage IV Hodgkin lymphoma whose disease has not been treated
Lymphoma
Lymphomatous meningitis (lymphoma that has spread to the meninges). It is given as intrathecal therapy
Mantle cell lymphoma in adults who have received at least one other type of treatment
Mantle cell lymphoma in patients who have already received at least one other type of treatment
Mantle cell lymphoma in patients who have received at least one other treatment
Mantle cell lymphoma in patients whose disease has recurred (come back) or has gotten worse after two other treatments, including bortezomib
Marginal zone lymphoma. It is used in patients who have received at least one other CD20-targeted therapy
Mycosis fungoides (a type of cutaneous T-cell lymphoma) in patients whose disease has the CD30 protein and who have received other systemic therapy
Mycosis fungoides (a type of cutaneous T-cell lymphoma)
Mycosis fungoides (a type of cutaneous T-cell lymphoma) that is advanced
Non-Hodgkin lymphoma
Non-Hodgkin lymphoma (NHL)
Non-Hodgkin lymphoma (NHL) that has recurred (come back). It is used in patients who have already received at least two systemic treatments. It is used in the following types of NHL--Follicular B-cell non-Hodgkin lymphoma
Non-Hodgkin lymphoma that is advanced
Non-Hodgkin lymphoma. It is used with other drugs in patients whose disease has not gotten better with other treatment or has recurred (come back)
Non-hodgkin lymphoma (certain types)
Non-small cell lung cancer that is anaplastic lymphoma kinase (ALK) positive and has metastasized (spread to other parts of the body). It is used in patients whose disease got worse after treatment with:Crizotinib and at least one other ALK inhibitor therapy for metastatic disease, or
Non-small cell lung cancer that is anaplastic lymphoma kinase (ALK) positive and has metastasized (spread to other parts of the body)
Non-small cell lung cancer that is anaplastic lymphoma kinase (ALK) positive and has metastasized (spread to other parts of the body)
Non-small cell lung cancer that is anaplastic lymphoma kinase (ALK) positive and has metastasized (spread to other parts of the body). Brigatinib is used in patients whose cancer cannot be treated with crizotinib or got worse while taking crizotinib
Non-small cell lung cancer that is anaplastic lymphoma kinase (ALK) positive or ROS1 positive and has metastasized (spread to other parts of the body)
Oral mucositis that is severe. It is used in patients with leukemia or lymphoma who are being treated with high-dose chemotherapy and radiation therapy, followed by stem cell rescue
Peripheral T-cell lymphoma in patients who have already been treated with at least one other type of therapy
Peripheral T-cell lymphoma in patients whose disease has not gotten better with other chemotherapy or has recurred (come back)
Peripheral T-cell lymphoma in patients whose disease has recurred (come back) or is refractory (does not respond to treatment)
Peripheral T-cell lymphoma that has the CD30 protein. It is given with cyclophosphamide, doxorubicin hydrochloride, and prednisone
Primary mediastinal large B-cell lymphoma
Primary mediastinal large B-cell lymphoma. It is used in adults and children whose disease is refractory or has relapsed after at least two other therapies.????
Skin problems caused by cutaneous T-cell lymphoma that have not gotten better with other treatment
Small lymphocytic lymphoma
T-cell lymphoblastic lymphoma
Tumor lysis syndrome in patients with leukemia, lymphoma, or malignant solid tumors. It is used when the treatment is expected to cause high blood levels of uric acid
Waldenstr????m macroglobulinemia (a type of non-Hodgkin lymphoma)
With chemotherapy as first-line treatment in adults with stage II bulky, stage III, or stage IV follicular lymphoma. Patients who have at least a partial remission are then treated with obinutuzumab by itself